Treatment with prasugrel according to EU label recommendations results in a significant @ % and @ % relative risk reduction ( absolute risk reductions of @ % and @ % ) in ischemic events and stent thromboses respectively compared with clopidogrel , with a @ % relative risk increase ( absolute risk increase of @ % ) for major bleeds ( p = @ ) , and no excess of strokes .